title: Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet.
abstract: In a multicenter, randomized, placebo-controlled clinical trial of pertussis immune globulin, intravenous (P-IGIV), 25 infants hospitalized with pertussis were enrolled in 24 months (15% of the target sample size) before the study was prematurely terminated because of expiration of the P-IGIV lots and unavailability of additional study product. Although well tolerated, there was no difference in the number or rate of improvement of symptoms (paroxysmal cough, whoop, apnea, bradycardia, oxygen desaturations) in P-IGIV recipients compared with placebo.
authors.affiliation: Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada. scott.halperin@dal.ca
authors.forename: Scott A
authors.initials: SA
authors.lastname: Halperin
authors.forename: Wendy
authors.initials: W
authors.lastname: Vaudry
authors.forename: Francois D
authors.initials: FD
authors.lastname: Boucher
authors.forename: Kate
authors.initials: K
authors.lastname: Mackintosh
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Waggener
authors.forename: Bruce
authors.initials: B
authors.lastname: Smith
mesh_terms: D001886:Bordetella pertussis / Q000276:immunology*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D014917:Whooping Cough / Q000276:immunology / Q000628:therapy*
chemical_list: D016756:Immunoglobulins, Intravenous